AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2823313
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LTB4 and PGE2
Trial: 28448398
Drug: 150 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg/kg EREM
Trial: 28448398
Drug: 7.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg/kg IT morphine
Trial: 23758655
Drug: Primary surgery
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary surgery followed by adjuvant chemotherapy (6 cycles of Epirubicin, cisplatin, 5-fluorouracil)
Trial: 23758655
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (2x3 cycles of Epirubicin, cisplatin, 5-fluorouracil)
Trial: 21963186
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment during spontaneous breathing via a thin catheter
Trial: 18342224
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (optimal medical therapy without hemodynamic monitoring)
Trial: 11303053
Drug: Celecoxib in
RxNorm normalized name: Product containing celecoxib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib in solution
Trial: 11303053
Drug: Celecoxib in
RxNorm normalized name: Product containing celecoxib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib in capsule
Trial: 11303053
Drug: Celecoxib intragastrically
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib intragastrically in solution
Trial: 9076853
Drug: No psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No psychiatric treatment group
Trial: 25347968
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with 75.4 g kg(‐1) lipid level
Trial: 25347968
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with 51.4 g kg(‐1) lipid level
Trial: 10917072
Drug: Class II
RxNorm normalized name: HLA class II antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class II agents (beta-blockers)
Trial: 8371471
Drug: Class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I antiarrhythmic agents
Trial: 9114762
Drug: d,l-sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-sotalol
Trial: 10917072
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (class IV agents)
Trial: 1904750
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ritanserin
Trial: 28039798
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (5-week supply)
Trial: 22225544
Drug: Probiotic-enriched artichokes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-enriched artichokes (180 g per day, 2 × 10(10) CFU of Lactobacillus paracasei IMPC 2.1)
Trial: 20128566
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intravitreal dexamethasone
Trial: 20128566
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg intravitreal dexamethasone
Trial: 17585971
Drug: 150 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/kg TYR (total 300 mg/kg)
Trial: 15750360
Drug: Homeopathic combination
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic combination medicine
Trial: 11876695
Drug: Pantoprazole, 40
RxNorm normalized name: Pantoprazole, 40 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole, 40 mg once daily
Trial: 1673233
Drug: bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol 10 mg o.d.
Trial: 1673233
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 mg o.d.
Trial: 324577
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for mild hypertension
Trial: 24861837
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy with TCM
Trial: 24067192
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (50, 150, or 300 mg/day)
Trial: 18612923
Drug: Etanercept in
RxNorm normalized name: etanercept Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept in combination with methotrexate (MTX)
Trial: 11847165
Drug: No ACE
RxNorm normalized name: Amino Acetic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACE inhibitor treatment (Control)
Trial: 1790147
Drug: Recombinant gamma-interferon
RxNorm normalized name: gamma-interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant gamma-interferon (rGIFN) as a 2-h intravenous infusion daily x 5 every other week at a starting dose of 4.0 x 10(6) IU/m2/day (arm I)
Trial: 1790147
Drug: Recombinant gamma-interferon
RxNorm normalized name: gamma-interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant gamma-interferon (rGIFN) as a 24-h continuous intravenous infusion daily x 5 every month at a starting dose of 2.6 x 10(6) IU/m2/day (arm II)
Trial: 27807735
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg body weight oral GHB before going to bed
Trial: 21362312
Drug: Shensongyangxin (SSYX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shensongyangxin (SSYX) capsule
Trial: 21362312
Drug: Mexiletine tablet
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mexiletine tablet
Trial: 16905632
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation antipsychotics (amisulpride)
Trial: 16905632
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation antipsychotics (olanzapine)
Trial: 16905632
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics (CAs)
Trial: 15070934
Drug: Cabergoline treatment
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline treatment for 24 months
Trial: 10989854
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg rocuronium
Trial: 11455866
Drug: 0.075 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg vecuronium
Trial: 2310658
Drug: 10% glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glycerol in saline (500 ml over 4 h on 6 consecutive days)
Trial: 15055892
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment with saline
Trial: 28512921
Drug: Integrated Bipolar
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Bipolar Parenting Intervention (IBPI) plus treatment as usual (TAU)
Trial: 25557952
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg/day) and Sofosbuvir (400 mg/day)
Trial: 25557952
Drug: Peginterferon alfa
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa 2b (1.5 mcg/kg/wk), Ribavirin (1000-1200 mg/day), and Sofosbuvir (400 mg/day)
Trial: 15564951
Drug: Prophylactic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic epidural blood patch with 20 ml autologous blood
Trial: 7802571
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibiotic therapy)
Trial: 3292578
Drug: Muscle stretching
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle stretching treatment
Trial: 30376130
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg EOW)
Trial: 31713184
Drug: Calcitriol 0.25
RxNorm normalized name: CALCITRIOL 0.25MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.25 μg three times daily from transplantation to day 30
Trial: 24284618
Drug: Sublingual nucleotides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nucleotides (50 mg/day) for 14 days
Trial: 21766553
Drug: L-isoleucine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-isoleucine (2 g/L)-added ORS
Trial: 21766553
Drug: ORS without
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS without L-isoleucine (control)
Trial: 8380295
Drug: NWTS-1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NWTS-1 treatment regimen
Trial: 8380295
Drug: NWTS-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NWTS-2 treatment regimen
Trial: 8380295
Drug: NWTS-3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NWTS-3 treatment regimen
Trial: 8380295
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with specimen weight 550 g or greater
Trial: 3946161
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (0.25 mg/kg)
Trial: 3946161
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (0.25 mg/kg) in patients receiving long-term propranolol (120 to 240 mg/day)
Trial: 23104611
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections
Trial: 23104611
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections
Trial: 23104611
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Trial: 23104611
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Trial: 2589654
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (100 mg)
Trial: 12670813
Drug: Morphine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (3 mg)
Trial: 12670813
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (100 mg) + Morphine (3 mg)
Trial: 10392225
Drug: Blood sample
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood sample obtained from normal saline lock after discarding 2 times the dead space (3 mL)
Trial: 31652009
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation
Trial: 31666344
Drug: R-HDS (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-HDS (high-dose chemotherapy with rituximab and autograft)
Trial: 31666344
Drug: CHOP-R (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP-R (conventional chemotherapy with rituximab)
Trial: 22036059
Drug: Intrathecal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal dexamethasone (8 mg) with intrathecal morphine (0.2 mg)
Trial: 22036059
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline solution with intrathecal morphine 0.2 mg)
Trial: 20118683
Drug: 2-dose priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-dose priming with PHiD-CV
Trial: 20118683
Drug: 3-dose priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-dose priming with PHiD-CV
Trial: 24709264
Drug: Resiquimod 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resiquimod 0.01% gel
Trial: 14697444
Drug: Sorbolene cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbolene cream (10% glycerin)
Trial: 2670647
Drug: Famotidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (1 tablet of 40 mg at night)
Trial: 2670647
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 tablets of 150 mg at night)
Trial: 805649
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G, 4.8 million units IM in one session plus 1.0 g probenecide
Trial: 805649
Drug: Tetracycline HCI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline HCI, 9 g over 4 days
Trial: 805649
Drug: Trimethoprim, 80
RxNorm normalized name: Sulfamethoxazole-Trimethoprim, 80 mg-16 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim, 80 mg-sulfamethoxazole, 400 mg (TMP-SMX) six tablets once daily for 3 days
Trial: 805649
Drug: TMP-SMX, six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMX, six tablets twice on 1 day at a 6-hour interval
Trial: 28945869
Drug: Prednisolone (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (37.5 mg/d)
Trial: 25449342
Drug: CC with
RxNorm normalized name: BD Syringe 5cc with Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC with audio-visual feedback device
Trial: 25449342
Drug: CC without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CC without audio-visual feedback device
Trial: 18477268
Drug: Mannitol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (0.5 g x kg(‐1) in pump prime)
Trial: 15232337
Drug: Naltrexone in
RxNorm normalized name: naltrexone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone in combination with clonazepam
Trial: 11382108
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding started in the 1st postoperative week
Trial: 3118746
Drug: Nebulized atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized atropine methonitrate (anticholinergic bronchodilator)
Trial: 3118746
Drug: Metaproterenol hydrochloride
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol hydrochloride (beta-adrenergic bronchodilator)
Trial: 26323489
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 4 µg kg(‐1) (Group 2)
Trial: 26323489
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 3 µg kg(‐1) (Group 1)
Trial: 11127760
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone acetate / 10 microg ethinyl estradiol
Trial: 11127760
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone acetate / 5 microg ethinyl estradiol
Trial: 11127760
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg norethindrone acetate / 2.5 microg ethinyl estradiol
Trial: 8450526
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard (20 mg twice daily)
Trial: 2412034
Drug: Ketanserin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (120 mg/day)
Trial: 31364875
Drug: Synbiotic powder
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic powder containing Lactobacillus reuteri (108 CFU) and soluble fiber (4.3 g)
Trial: 29717175
Drug: Ginger capsules
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger capsules
Trial: 24559600
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate capsules
Trial: 18494974
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation (diamond bur + 37% phosphoric acid) (Group 1)
Trial: 7538703
Drug: HCR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCR therapy (hyperthermia combined with chemotherapy and irradiation)
Trial: 7538703
Drug: CR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR therapy (chemo-radiotherapy)
Trial: 7538703
Drug: HCR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCR therapy
Trial: 7538703
Drug: CR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR therapy
Trial: 2185968
Drug: Octreotide injections
RxNorm normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide injections (100 micrograms t.i.d.)
Trial: 30679336
Drug: bupivacaine 13
RxNorm normalized name: bupivacaine 132 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 13 mg with intrathecal fentanyl 20 µg (Group BF)
Trial: 30679336
Drug: bupivacaine 13
RxNorm normalized name: bupivacaine 132 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 13 mg (Group B)
Trial: 21235787
Drug: rostafuroxin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rostafuroxin 0.05 mg/d
Trial: 21235787
Drug: rostafuroxin 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rostafuroxin 0.15 mg/d
Trial: 21235787
Drug: rostafuroxin (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rostafuroxin (combined dosage arms)
Trial: 19208731
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g EAA/d for 3 months (supplemented treatment group)
Trial: 17536125
Drug: Pistachio nut
RxNorm normalized name: pistachio nut
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio nut diet (15% of daily caloric intake)
Trial: 10819701
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine hydrochloride, 0.1 mg/d
Trial: 8632299
Drug: Triazolam (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125 mg) preceded by ketoconazole
Trial: 8632299
Drug: Triazolam (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125 mg) preceded by placebo
Trial: 22245724
Drug: Flax drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax drink (2.5 g of soluble fibers)
Trial: 22245724
Drug: Flax tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax tablets (2.5 g of soluble fibers)
Trial: 22245724
Drug: CONTROL (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONTROL (300 mL drink)
Trial: 19914563
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments including surgery, chemotherapy, molecular therapy, radiation therapy, immunotherapy, and palliative therapy
Trial: 18401903
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin 20 mg twice a day along with topical clindamycin (1%) and adapalene (0.1%) for 24 weeks
Trial: 18401903
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin only
Trial: 8543495
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g every 8 h, infusion or bolus)
Trial: 8543495
Drug: Imipenem/cilastatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (1 g every 8 h, infusion)
Trial: 30840384
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose antioxidant supplementation (vitamins and minerals) for 7.5 years
Trial: 15796636
Drug: Personal construct
RxNorm normalized name: Alstonia constricta bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal construct group therapy
Trial: 7805903
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg twice per day for 14 days
Trial: 7805903
Drug: Trimethoprim 160
RxNorm normalized name: trimethoprim 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 160 mg-sulfamethoxazole 800 mg twice per day for 14 days